Cohort Study

Comparative study of the safety and efficacy of SMOFlipid vs non-SMOFlipid as TPN for liver transplantation

Mei-Yun Wu a,b, Sheng-Chih Kuo c, Su-Fen Chuang d, Cheng-Hsi Yeh c, Shih-Min Yin c, Wei-Feng Li c, Hung-Jen Wang e, Chao-Long Chen c, Chih-Chi Wang c, Chih-Che Lin e,*

a College of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan
b Department of Nursing, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
c Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
d Dietitian, Department of Nutritional, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
e Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan

ARTICLE INFO

Keywords:
Liver transplantation
SMOFlipid
Fish oil

ABSTRACT

Background: Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease. Nutrition impacts its success. Total parenteral nutrition (TPN) is usually prescribed for patients recommended prolonged fasting after LT. The supplement of SMOFlipid (soybean oil, MCT oil, olive oil, and fish oil) is easily metabolised to produce energy, and it possesses anti-inflammatory effects; however, SMOFlipid emulsion use raises concerns regarding coagulopathy after LT. This study investigated the postoperative correlation between SMOFlipid and coagulation in LT.

Materials and methods: The medical records of 54 recipients of living donor LT between January 2012 and June 2015 were retrospectively reviewed. Patients with pretransplant platelet count <40,000/μL and >40,000/μL were assigned to the non-SMOFlipid (n = 23) group and the SMOFlipid (n = 31) group, respectively.

Results: The coagulation and nutrition profile of patients improved significantly after TPN support. No significant difference was observed in the coagulation profile between SMOFlipid and non-SMOFlipid groups. Although the SMOFlipid group exhibited a higher platelet count than the non-SMOFlipid group on day 7 (P < 0.001), no significant differences were observed in the platelet count on 14 and 30 days after TPN support between the 2 groups.

Conclusion: TPN using SMOFlipid after LT is a good strategy for improving nutritional status without increasing the risks of bleeding and coagulation in patients intolerant of early enteral nutrition. Moreover, SMOFlipid use may not cause coagulopathy up to 14 days after LT. Overall, SMOFlipid provides nutritional benefits without increasing the risk of bleeding.

1. Introduction

Liver failure is characterised by the loss of liver function and is complicated with hepatic encephalopathy and coagulopathy [1–3]. Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease [2,4]. Malnutrition is one of the common manifestations of this critical condition and is also an independent predictor of mortality [3–5]. Several studies have shown that malnutrition is a poor prognostic factor for LT, which indicates that nutritional support may reduce LT complications and improve survival [4].

Total parenteral nutrition (TPN) is usually prescribed for patients recommended prolonged fasting after LT. The supplement of SMOFlipid (soybean oil, MCT oil, olive oil, and fish oil) has the advantage of being easily metabolised to produce energy, and it has anti-inflammatory effects [6–8]. The major therapeutic mechanism of fish oil is the attenuation of systematic inflammation, which may decrease the mortality risk in patients with severe injury and sepsis [9,10]. SMOFlipid has been proven to be safe and well tolerated in a wide range of clinical conditions, and it is used as the standard lipid emulsion [11,12]. Moreover, the short-term application of parenteral fish oil with soybean oil not only significantly reduces the parameters of liver damage in the
postoperative period but also leads to a more balanced immune response, which may result in the faster resolution of inflammation and recovery [10,13]. However, SMOFlipid emulsion use may be associated with coagulopathy after LT [14]. Early studies have shown that the dietary intake of n-3 fatty acids, which is a component of fat, is associated with antithrombotic effects but increases the risk of bleeding [15]. A detailed analysis is lacking, and these observations have yet to be proven; this concern persists [16,17]. Hence, we should pay attention to the bleeding tendency when using fish oil fat emulsion because it may aggravate the risk of bleeding. Therefore, the use of fish oil-containing fat emulsion and its related risks is a clinically important issue in early LT that should be investigated, because liver function is not restored immediately after transplantation, and there is a tendency of coagulopathy. Thus, classical haemostasis parameters such as activated partial thromboplastin time (aPTT) and platelet count are measured prior to surgery and before the start of TPN. However, many questions remain unanswered regarding nutritional assessment and support for these seriously ill, nutritionally, and metabolically complex patients [13]. This study evaluated the effect of the SMOFlipid supplement in TPN in LT patients.

2. Materials and methods

2.1. Study design

This study was approved at ClinicalTrials.gov (ID: NCT04572373) and has been reported in line with the STROCSS criteria [18]. Adult patients who underwent LT at Kaohsiung Chang Gung Memorial Hospital between January 2012 and June 2015 were screened in this study. The medical records of patients were retrospectively reviewed to check if TPN was provided in the last 14 days in the peri-transplantation period.

The study evaluated the effect of the SMOFlipid supplement in TPN in LT patients.

2.2. Patient selection

A total of 54 adult (age > 18 years) LT recipients were enrolled, excluding those with renal dysfunction (eGFR < 60 mL/min/1.73 m²). On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10–14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more.

2.2. Patient selection

A total of 54 adult (age > 18 years) LT recipients were enrolled, excluding those with renal dysfunction (eGFR < 60 mL/min/1.73 m²). On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group (n = 23) and the SMOFlipid group (n = 31), respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.

2.3. Operative procedures and postoperative care

The surgical procedures of liver transplantation are described elsewhere [19–22]. After portal vein anastomosis, the graft was re-perfused by consecutively unclamping the hepatic and portal veins. The hepatic artery was subsequently anastomosed, followed by biliary anastomosis. Venous outflow reconstruction was performed by anastomosing the donor and recipient hepatic veins in an end-to-end manner. Hepatic artery reconstruction was performed by a microsurgeon using the microsurgical technique. The types of biliary reconstruction and drainage to be provided to patients were judged by the same microsurgeon according to the diameter, number, and viability of the bile ducts, and the biliary reconstruction and drainage were performed using microsurgery. After transplantation, liver ECHO with Doppler was conducted daily for at least 14 days to detect early vascular complications.

For immunosuppression, methylprednisolone, Tacrolimus, and Mycophenolate mofetil were used. Basiliximab was initiated after portal vein re-perfusion and on postoperative day 4. Tacrolimus treatment was initiated on postoperative day 1, and a trough plasma concentration of 8–10 ng/mL was maintained during the first month and 5–8 ng/mL thereafter. Antithrombotic treatment consisted of heparin and PGE1 use for the first 7–14 days postoperatively.

2.4. Data collection

The study patients were divided into the SMOFlipid group (n = 31) and a non-SMOFlipid group (n = 23). Medical records including patient demographics, preoperative history, physical examination, clinical course, laboratory studies, aetiology of liver disease, severity of liver disease including Child-Pugh score and the Model for End-Stage Liver Disease (MELD) score, postoperative complications, and length of ICU and hospital stay were collected and reviewed.

2.5. Ethics

This study was performed after approval from the Committee on Ethics in Clinical Research of the Kaohsiung Chang Gung Memorial Hospital, Taiwan (IRB number: 201601322A3). All patients were explained the objectives and possible adverse reactions of the supplement used in the study. Patients provided voluntarily written informed consent prior to their enrolment into the study or before they received supplementation with the fat emulsion.

2.6. Statistical analysis

Numerical variables are presented as mean ± SD, unless indicated otherwise. Statistical analyses were performed using SPSS version 22. One-way ANOVA and Scheffe’s method were used to analyse changes with time within the treatment groups. The t-test was used to compare variables between different time points and to compare the variables between groups at a particular time point. Linear correlations were determined using Pearson’s correlation coefficients. P < 0.05 was considered statistically significant.

3. Results

A total of 54 patients who underwent LT between 1 January 2012 and 30 June 2015 received TPN. Of them, 49 patients underwent living donor LT, and the other 5 patients underwent deceased donor LT. The total number of deaths within 14 and 30 days of LT were zero and 2, respectively.

3.1. Patient demographics and clinical characteristics of SMOFlipid and non-SMOFlipid groups

Patient demographics and clinical characteristics showed no significant difference between the SMOFlipid and non-SMOFlipid groups in terms of aetiology and severity of liver disease (Child–Pugh classification and MELD score). The non-SMOFlipid group had a longer length of hospital stay than the SMOFlipid group; however, no significant difference was observed (Table 1).

| Characteristic                  | SMOFlipid Group (n=31) | Non-SMOFlipid Group (n=23) |
|--------------------------------|------------------------|-----------------------------|
| Age (years)                    | 54 ± 8                 | 62 ± 10                     |
| Gender (M/F)                   | 25/8                   | 17/12                       |
| Body Mass Index (kg/m²)        | 24 ± 4                 | 26 ± 5                      |
| Preoperative history (days)    | 13 ± 7                 | 17 ± 8                      |
| Preoperative history (days)    | 13 ± 7                 | 17 ± 8                      |

Table 1: Patient demographics and clinical characteristics of SMOFlipid and non-SMOFlipid groups.
3.2. Improvement of coagulation profile after nutrition support in SMOFlipid and non-SMOFlipid groups

The effects of nutrition support on coagulation statuses are presented in Fig. 1. During nutrition support, all coagulation parameters namely prothrombin time (PT), international normalized ratio (INR), aPTT, and platelet count improved gradually in both the SMOFlipid and non-SMOFlipid groups (Tables 2 and 3). The non-SMOFlipid group exhibited lower platelet count than the SMOFlipid group 7 days after TPN support (Fig. 1); however, no significant differences on 14 and 30 days after TPN support were observed in platelet counts between the groups (Fig. 1).

3.3. Improvement of nutrition profile after nutrition support in SMOFlipid and non-SMOFlipid groups

The 3 nutritional parameters, namely albumin, cholesterol, and triglyceride levels, also improved gradually after nutrition support (Fig. 1 and Tables 2 and 3). Cholesterol and triglyceride levels showed no significance between the non-SMOFlipid and SMOFlipid groups. We reported no bleeding events, such as postoperative intra-abdominal bleeding, upper gastrointestinal bleeding, or intra-cranial haemorrhage, in our care group.

4. Discussion

Postoperative nutrition support is critical for LT recipients. Our findings indicate that TPN support using SMOFlipid is safe and efficient for improving the nutritional status of patients, and SMOFlipid use does not impair coagulation parameters and does not increase the risk of thrombocytopenia.

The classical hemostatic parameters, such as prothrombin time (PT), aPTT, and platelet counts, were measured before TPN support and on 7, 14, and 30 days after TPN support. In the post-TPN observation period, the coagulation capacity was regained. As hypothesised, no differences were observed in PT, aPTT, and platelet counts. Overall, SMOFlipid administration was shown to be safe without increased coagulation risk and did not influence the platelet count [11,16].

Protein-energy malnutrition and metabolic abnormalities are common in patients with end-stage liver disease who undergo LT [14]. The malnutrition may further increase morbidity, mortality, and costs in the post-transplantation setting [14,23]. Thus, nutritional support during all phases of LT is crucial; although enteral nutrition is preferred, parenteral nutrition may be provided to supply the required calorie intake (14). Therefore, administration of SMOFlipid in the postoperative period can be considered valuable for patients requiring parenteral nutrition after major abdominal surgery [24]. In our series, SMOF lipid as nutrition support after LT showed benefits in the short term. However, it should be investigated whether this intervention has benefits after long-term use.

In addition, the nutritional status in LT recipients can worsen rapidly in the immediate post-transplantation period due to preoperative malnutrition, immunosuppressive therapy, fasting, surgical stress, and postinterventional complications [23,25]. However, nutrition support with lipid supplements also raises the concern of possible adverse effects, such as prolonged bleeding time, thrombocytopenia, coagulation disorders, hyperlipidaemia, and deteriorating liver function [16,17]. These anti-hemostatic consequences might lead to bleeding complications, prolonged hospital stay, and surgical mortality after LT. In our series, the application of SMOFlipid improved the nutritional status in LT recipients, with no evident increase in the risks of bleeding, surgical mortality, and thrombocytopenia. Thus, these findings indicate that an aggressive early postoperative nutritional support (via the enteral route, if possible) with lipid-containing agents should be provided to patients with the highest MELD score, without any concern for the bleeding tendency [23].

ω-3 (n-3) fatty acids are essential polyunsaturated fatty acids derived from fish oil. The benefits of nutritional supplementation with ω-3 fatty acids in decreasing postoperative infection complications and length of hospital stay have been proven in patients undergoing elective gastrointestinal surgery, particularly in those with preoperative malnourishment [3,26]. Therefore, post-transplant partial parenteral nutrition support can greatly improve the protein metabolism and nutritional states. A study also showed that ω-3 fatty acid supplementation for parenteral nutrition significantly decreases injury of the transplanted liver, incidence of infectious morbidities, and the post-transplant hospital stay [14,27]. Our study also demonstrated a similar effect of nutrition support with SMOFlipid without the risk of SMOFlipid-related adverse events, such as postoperative bleeding and thrombocytopenia. Therefore, SMOFlipid might provide a safe and efficient nutrition support in critical patient care after LT.

In addition to the effects of lipid emulsions on coagulation and nutritional status, studies have discussed their effects on the inflammatory response. SMOFlipids are enriched with w-3 fatty acids and thus inhibit the production of proinflammatory cytokines [6–8], and they are considered beneficial for patients at risk of inflammation [28,29]. Furthermore, fish oil supplements for surgical [30] and critically ill patients [31] are recommended by the European Society of Clinical Nutrition and Metabolism. In this study, we only focused on the effects of SMOFlipid supplements on coagulation and nutritional status after liver transplantation in patients. The anti-inflammatory effects were not evaluated in surgical and critically ill patients and warrant investigation.

5. Conclusion

TPN after LT is an effective strategy for improving nutrition and coagulation in patients exhibiting early enteral feeding intolerance. Additionally, the use of SMOFlipid may not cause coagulopathy up to 14 days after LT. Thus, SMOFlipid provides nutritional benefits without increasing the risk of bleeding.
Fig. 1. Comparison of coagulation parameters (PT(A), INR(B), APTT(C), Platelet(D)) and nutrition parameters (Albumin(E), Cholesterol(F), Triglyceride(G)) between both groups.

The serum level of INR (A) APTT (B) Platelet (C) Albumin (D) Cholesterol and (E)Triglyceride (F) with or without using SMOF; *:significantly different between the two group.
SMOFlipid, Soybean oil, MCT oil, Olive oil, Fish oil; PT, Prothrombin Time; INR, International normalized ratio; aPTT, activated Partial Thromboplastin Time.

Table 2

Coagulopathy profile and nutrition profile in SMOFlipid group.

|                | 7 days vs. 14 days | 7 days vs. 30 days | 14 days vs. 30 days | Sphericity Assumed |
|----------------|-------------------|-------------------|-------------------|-------------------|
| **PT (sec)**   | 0.124             | 0.044*            | 0.103*            | 0.033*            |
| **INR (sec)**  | 0.060             | 0.012*            | 0.042*            | 0.005*            |
| **aPTT (sec)** | 0.002*            | 0.0001*           | 0.002*            | 0.0001*           |
| **Platelet (10^3/μL)** | 0.022*           | 0.0001*           | 0.187*            | 0.002*            |
| **Albumin (g/μL)** | 0.280         | 0.046*            | 0.119             | 0.045*            |
| **Cholesterol (mg/dL)** | 0.0001*       | 0.0001*           | 0.0001*           | 0.0001*           |
| **Triglyceride (mg/dL)** | 0.006*        | 0.006*            | 0.360             | 0.007*            |

30 days after nutrition support in SMOFlipid group, all coagulation and nutrition parameters showed significant difference (p < 0.05) when comparing with 7 days after nutrition support.

Table 3

Coagulopathy profile and nutrition profile in non-SMOFlipid group.

|                | 7 days vs. 14 days | 7 days vs. 30 days | 14 days vs. 30 days | Sphericity Assumed |
|----------------|-------------------|-------------------|-------------------|-------------------|
| **PT (sec)**   | 0.347             | 0.011*            | 0.064             | 0.027*            |
| **INR (sec)**  | 0.983             | 0.021*            | 0.075             | 0.020*            |
| **aPTT (sec)** | 0.540             | 0.0001*           | 0.007*            | 0.0001*           |
| **Platelet (10^3/μL)** | 0.023*         | 0.013*            | 0.992             | 0.023*            |
| **Albumin (g/μL)** | 0.101         | 0.062             | 0.179             | 0.063             |
| **Cholesterol (mg/dL)** | 0.018*        | 0.0001*           | 0.0001*           | 0.0001*           |
| **Triglyceride (mg/dL)** | 0.451         | 0.026*            | 0.076             | 0.021*            |

30 days after nutrition support in non-SMOFlipid group, coagulation and nutrition parameters showed significant difference (p < 0.05) except for albumin level when comparing with 7 days after nutrition support. SMOFlipid, Soybean oil, MCT oil, Olive oil, Fish oil; PT, Prothrombin Time; INR, International normalized ratio; aPTT, activated Partial Thromboplastin Time.

As shown previously, the application of intravenous SMOFlipid as a component of the mixed type emulsion is not associated with any negative effects including the risk of coagulopathy. Furthermore, the significance of carefully assessing the nutritional status during the work-up for patients who are candidates for LT is widely recognised. Additionally, this approach should be considered when patients cannot tolerate oral intake. On the basis of our findings, for patients with platelet counts higher than 40,000/μL, although the nutritional status after SMOFlipid supplements was similar to that in the non-SMOFlipid lipid group, the administration of SMOFlipid TPN was safe, with no evident coagulopathy or worsening thrombocytopenia.

5.1. Limitation

In this study, we enrolled only 54 patients of the 147 patients who underwent TPN support after LT between 1 January 2012 and 30 June 2015. Furthermore, the retrospective design of the study may have affected the quality of the obtained data. In addition, we excluded patients with extreme thrombocytopenia (platelet count < 40,000/μL), and the anti-inflammatory effects of SMOFlipid were not assessed in this study. Furthermore, coagulopathy and thrombocytopenia might be associated not only with nutrition supplementation but also with other clinical conditions, including medication usage, graft quality, sepsis, and other complications, in LT recipients. Moreover, the components of SMOFlipid are complicated; determination of the individual effects of each component, such as ω-3 or ω-6 fatty acids, on LT recipients requires further analysis. Further larger, prospective, randomised studies are required to determine whether SMOFlipid provides benefit in terms of both nutrition and postoperative recovery in LT recipients.

Grant information

This work was supported by Grant CMRPG8F0971, CMRPG8F0972, CMRPG8F0981 and CMRPG8F0982 from the Chang Gung Memorial Hospital, R.O.C.

Author contribution

Mei-Yun Wu; concept of study, data collection, data analysis, writing paper, Sheng-Chih Kuo; concept of study, writing paper, Su-Fen Chuang; data collection, Cheng-Hsi Yeh; data collection, Shih-Min Yin; data collection, Wei-Feng Li; data collection, Hung-Jen Wang; data collection, Chao-Long Chen; concept of study, Chih-Chi Wang; concept of study, Chih-Che Lin; concept of study, critical manuscript.

Registration of research studies

Research Registry Unique Identifying Number: ClinicalTrials.gov, Registration ID: NCT04572373.

Guarantor

Wipusit Taesombat.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

All of authors in this study declared that there were no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jamsu.2021.01.042.

References

[1] A. Koffron, J.A. Stein, Liver transplantation: indications, pretransplant evaluation, surgery, and posttransplant complications, Med. Clin. 92 (4) (2008) 861–888, ix.
[2] M. Merli, M. Giusto, V. Giannelli, C. Lucidi, G. Riggio, Nutritional status and liver transplantation, J Clin Exp Hepatol 1 (3) (2011) 190–196.
[3] J. Xu, Z. Yunshi, R. Li, Immunonutrition in surgical patients,Curr. Drug Targets 10 (8) (2009) 771–777.
[4] A.J. Kerwin, M.S. Nuxbaum, Adjuvant nutrition management of patients with liver failure, including transplant, Surg. Clin. 91 (3) (2011) 565–578, 578.
[5] A.S. Henkel, A.L. Buchanan, Nutritional support in patients with chronic liver disease, Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (4) (2006) 202–209.
[6] S. Bolisetty, D. Osborn, J. Sinn, K. Lai, Australasian Neonatal Parenteral Nutrition Consensus G, Standardised neonatal parenteral nutrition formulations - an Australasian group consensus 2012, BMC Pediatr. 14 (2014) 48.
[7] H. Li, X.Z. Ruan, S.H. Powis, R. Fernando, W.Y. Mon, D.C. Wheeler, et al., EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism, Kidney Int. 67 (3) (2005) 867–874.
[8] P.C. Calder, P. Yaqoob, Understanding omega-3 polyunsaturated fatty acids, Postgrad. Med. 121 (6) (2009) 148–157.
[9] C. Wei, J. Hua, C. Bin, K. Klassen, Impact of lipid emulsion containing fish oil on outcomes of surgical patients: systematic review of randomized controlled trials from Europe and Asia, Nutrition 26 (5) (2010) 474–481.
[10] W. Manzanares, P.L. Langlois, R. Dhillon, M. Lemiex, D.K. Heyland, Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis, Crit. Care 19 (2015) 167.
[11] S. Klek, C. Chamberier, P. Singer, M. Rubin, T. Bowling, M. Staun, et al., Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid)–a double-blind, randomised, multicentre study in adults, Clin. Nutr. 32 (2) (2013) 224–231.
[12] P. Nandivada, G.L. Fell, K.M. Gura, M. Puder, Lipid emulsions in the treatment and prevention of parenteral nutrition-associated liver disease in infants and children, Am. J. Clin. Nutr. 103 (2) (2016), 629S-34S.

[13] X.H. Zhu, Y.F. Wu, Y.D. Qiu, C.P. Jiang, Y.T. Ding, Liver-protecting effects of omega-3 fish oil lipid emulsion in liver transplantation, World J. Gastroenterol. 18 (42) (2012) 6141-6147.

[14] A. Hammad, T. Kaido, V. Aliyev, C. Mandato, S. Uemoto, Nutritional therapy in liver transplantation, Nutrients 9 (10) (2017).

[15] H.R. Knapp, Dietary fatty acids in human thrombosis and hemostasis, Am. J. Clin. Nutr. 65 (5 Suppl) (1997), 1687S-98S.

[16] A.R. Heller, S. Fischer, T. Rossel, S. Geiger, G. Siegert, M. Ragaller, et al., Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery, Br. J. Nutr. 87 (Suppl 1) (2002) S95-S101.

[17] J. Mateu de Antonio, M. Florit-Sureda, Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients, Nutr. Hosp. 34 (1) (2017) 193-203.

[18] R. Agha, A. Abdal-Razak, E. Crossley, N. Dowlut, C. Iosifidis, G. Mathew, et al., STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156-165.

[19] T.E. Starzl, S. Iwatsuki, C.O. Esquivel, S. Todo, I. Kam, S. Lynch, et al., Refinements in the surgical technique of liver transplantation, Semin. Liver Dis. 5 (4) (1985) 349-356.

[20] H.P. Grewal, M.H. Shokouh-Amiri, S. Vera, R. Stratta, W. Bagous, A.O. Gabor, Surgical technique for right lobe adult living donor liver transplantation without venovenous bypass or portocaval shunting and with duct-to-duct biliary reconstruction, Ann. Surg. 233 (4) (2001) 502-508.

[21] K. Tanaka, S. Uemoto, Y. Tokunaga, S. Fujita, K. Sano, T. Nishizawa, et al., Surgical techniques and innovations in living related liver transplantation, Ann. Surg. 217 (1) (1993) 62-91.

[22] Y. Inomata, S. Uemoto, K. Asonuma, H. Egawa, Right lobe graft in living donor liver transplantation, Transplantation 69 (2) (2000) 258-264.

[23] G.R. Stephenson, E.W. Moretti, H. El-Moalem, P.A. Clavien, J.E. Tuttle-Newhall, Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation, Transplantation 72 (4) (2001) 666-670.

[24] M.W. Wichmann, P. Thul, H.D. Czarnetzki, B.J. Morlion, M. Kemen, K.W. Jauch, Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial, Crit. Care Med. 35 (3) (2007) 790-706.

[25] M. Merli, M. Giusto, F. Gentili, G. Novelli, G. Ferretti, O. Riggio, et al., Nutritional status: its influence on the outcome of patients undergoing liver transplantation, Liver Int. 30 (2) (2010) 298-214.

[26] I. Sukhotnik, A. Shany, Y. Bashenho, L. Hayari, E. Chemoedanov, J. Mogils, et al., Parenteral but not enteral omega-3 fatty acids (Omegaven) modulate intestinal regrowth after massive small bowel resection in rats, JPEN - J. Parenter. Enter. Nutr. 34 (5) (2010) 503-512.

[27] V.M. Baroba, E.A. Miles, C. Calhau, E. Lafuente, P.C. Calder, Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial, Crit. Care 14 (1) (2010) R5.

[28] P.C. Calder, Use of fish oil in parenteral nutrition: rationale and reality, Proc. Nutr. Soc. 65 (3) (2006) 264-277.

[29] P.C. Calder, Rationale and use of n-3 fatty acids in artificial nutrition, Proc. Nutr. Soc. 69 (4) (2010) 565-573.

[30] M. Braga, O. Ljungqvist, P. Soeters, K. Fearon, A. Weimann, F. Bozzetti, et al., ESPEN guidelines on parenteral nutrition: surgery, Clin. Nutr. 28 (4) (2009) 378-386.

[31] P. Singer, M.M. Berger, G. Van den Berghe, G. Biolo, P. Calder, A. Forbes, et al., ESPEN guidelines on parenteral nutrition: intensive care, Clin. Nutr. 28 (4) (2009) 387-400.